PACIFIC BIOSCIENCES OF CALIF (PACB)

US69404D1081 - Common Stock

1.8  +0.03 (+1.69%)

After market: 1.84 +0.04 (+2.22%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (11/22/2024, 8:00:02 PM)

After market: 1.84 +0.04 (+2.22%)

1.8

+0.03 (+1.69%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-3.74%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap492.95M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PACB Daily chart

Company Profile

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 796 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Company Info

PACIFIC BIOSCIENCES OF CALIF

1305 O'brien Drive

Menlo Park CALIFORNIA 94025

P: 16505218000

CEO: Christian O. Henry

Employees: 796

Website: https://www.pacb.com/

PACB News

News Image11 days ago - The Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The rock star money manager is starting to roll with the rallying market.

News Image15 days ago - PacBioPacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...

News Image16 days ago - PacBioPacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...

News Image16 days ago - PacBioPacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory...

News Image24 days ago - Volta Labs Inc.Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep

/PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the...

News Image25 days ago - PacBioPacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500

New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation...

PACB Twits

Here you can normally see the latest stock twits on PACB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example